On the mode of decrease of leukemic cells during treatment of acute leukemia.
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000611:Aminobiphenyl Compounds / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001215:Asparaginase / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology; D002470:Cell Survival / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D003561:Cytarabine / Q000031:analogs & derivatives / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007938:Leukemia / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D007958:Leukocyte Count; D008297:Male; D015122:Mercaptopurine / Q000627:therapeutic use; D008698:Mesylates / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D009504:Neutrophils; D011239:Prednisolone / Q000627:therapeutic use; D013997:Time Factors; D009353:Zinostatin / Q000627:therapeutic use
D000611:Aminobiphenyl Compounds; D000970:Antineoplastic Agents; D008698:Mesylates; D003561:Cytarabine; D009353:Zinostatin; D011239:Prednisolone; D015122:Mercaptopurine; D001215:Asparaginase; D008727:Methotrexate; D003630:Daunorubicin